Cardiovascular Disease

Climate change is sending more and more people unprepared for heatwaves to the nation’s emergency departments.

Antihypertensive medication initiation also linked to higher risk for severe falls requiring hospitalization, ED visits.

Two studies show recurrence within blanking period is associated with increased risk for recurrence in long term.

At this time, there have been no reports of adverse events associated with this recall.

Risks increased for stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, acute kidney injury.

Up to half of people with a cardiovascular risk factor did not see a primary care clinician or cardiologist in the past year

AB-1002 is an investigational one-time gene therapy that promotes increased production of protein inhibitor 1.

Hundreds of injuries and 14 deaths have been linked to the devices

Risk for experiencing acute cardiac event higher for adults with underlying cardiovascular disease

No reduction in risk for first hospitalization for heart failure or death seen among patients at increased risk for heart failure

Etidronate seems to slow progression of further vascular calcification

Dose-response relationship seen with risk heightened with longer duration exposure.

Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes

Lower risks for first heart failure hospitalization, total heart failure hospitalization seen with empagliflozin

Each SD increment in social determinants of health score linked to increased odds of diabetes, high BP, insufficient physical activity.

Inconsistent recommendations found for managing hypertensive urgencies, but outpatient BP goals were clearly defined.